Late recurrence in melanoma: clinical implications of lost dormancy.

PubWeight™: 1.18‹?› | Rank: Top 10%

🔗 View Article (PMC 3731060)

Published in J Am Coll Surg on May 03, 2013

Authors

Mark B Faries1, Shawn Steen, Xing Ye, Myung Sim, Donald L Morton

Author Affiliations

1: John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA 90404, USA. mark.faries@jwci.org

Associated clinical trials:

Tracing Dissemination of Melanoma Cells in Healthy Tissues (DISSEMELA) | NCT02854124

Articles cited by this

Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer (2007) 6.58

The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis. Clin Cancer Res (2006) 2.36

Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg (1990) 2.27

Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer (1997) 1.71

Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences? Ann Surg Oncol (2000) 1.64

Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med (2003) 1.53

The incidence of late recurrence (greater than 10 years); an analysis of 536 consecutive cases of cutaneous melanoma. Br J Plast Surg (1989) 1.21

Late recurrence of cutaneous melanoma. Arch Surg (1983) 1.16

Late relapse from cutaneous stage I malignant melanoma. Arch Surg (1985) 1.16

The effect of ageing on human lymphocyte subsets: comparison of males and females. Immun Ageing (2010) 1.14

Late metastases (beyond ten years) of cutaneous malignant melanoma. Literature review and case report. J Am Acad Dermatol (1986) 1.08

Late recurrence (beyond ten years) of cutaneous malignant melanoma. Report of two cases and a review of the literature. JAMA (1984) 1.08

Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol (2012) 1.01

Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). A single-centre analysis of 1881 patients with a follow-up of 10 years or more. J Eur Acad Dermatol Venereol (2010) 0.92

Late metastases of cutaneous melanoma: an analysis of 31 patients. J Am Acad Dermatol (2000) 0.91

The long-term clinical course of patients with cutaneous melanoma. Cancer (2002) 0.90

Late (> 10 years) recurrence of melanoma: the Scottish experience. Br J Dermatol (2003) 0.89

Prognostic parameters in recurrent malignant melanoma. Cancer (1983) 0.88

Characteristics associated with early and late melanoma metastases. Cancer (2010) 0.88

Late recurrence of localized cutaneous melanoma: its influence on follow-up policy. Plast Reconstr Surg (1990) 0.86

Late recurrence of malignant melanoma: a report of five cases, a review of the literature and a study of associated factors. Melanoma Res (1992) 0.83

Late recurrence of stage I malignant melanoma. J Surg Oncol (1989) 0.83

[First melanoma metastases after 10 years and more of remission]. Hautarzt (1997) 0.81

[Late metastasis of malignant cutaneous melanoma]. Hautarzt (1994) 0.78

[Late metastasis in malignant melanoma of the skin]. Dtsch Med Wochenschr (1989) 0.78

A case-control study of late recurrence of malignant melanoma. Am J Surg (1992) 0.78

Lack of predictive factors in late recurrence of stage I melanoma. Int J Dermatol (1992) 0.78

Malignant melanoma: significance of disease-free interval. Br J Radiol (1980) 0.78

Articles by these authors

Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08

A landscape of driver mutations in melanoma. Cell (2012) 12.61

Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32

Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol (2009) 3.36

Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24

The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02

Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J Clin Oncol (2008) 2.53

Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30

Prognostic impact of micrometastases in colon cancer: interim results of a prospective multicenter trial. Ann Surg (2007) 2.28

An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18

Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res (2004) 2.05

Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00

Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95

Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92

Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene (2004) 1.81

Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer (2004) 1.78

Prediction of disease outcome in melanoma patients by molecular analysis of paraffin-embedded sentinel lymph nodes. J Clin Oncol (2003) 1.78

Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol (2011) 1.78

CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res (2009) 1.77

FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res (2010) 1.73

Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res (2006) 1.72

BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition. Proc Natl Acad Sci U S A (2013) 1.72

Prognostic implications of thick (>or=4-mm) melanoma in the era of intraoperative lymphatic mapping and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.65

Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics (2011) 1.55

Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. JAMA Surg (2013) 1.52

Contemporary surgical treatment of advanced-stage melanoma. Arch Surg (2004) 1.52

Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol (2004) 1.50

Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol (2004) 1.44

Serum anti-ganglioside IgM antibodies in soft tissue sarcoma: clinical prognostic implications. Cancer J (2002) 1.43

Systemic irinotecan and regional floxuridine after hepatic cytoreduction in 185 patients with unresectable colorectal cancer metastases. Ann Surg Oncol (2002) 1.42

Preoperative imaging of pulmonary metastases in patients with melanoma: implications for minimally invasive techniques. Arch Surg (2012) 1.41

Serum TA90 immune complex assay can predict outcome after resection of thick (> or =4 mm) primary melanoma and sentinel lymphadenectomy. Ann Surg Oncol (2002) 1.39

Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol (2002) 1.38

New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol (2003) 1.34

Prediction of metastatic melanoma in nonsentinel nodes and clinical outcome based on the primary melanoma and the sentinel node. Mod Pathol (2004) 1.32

Authors' response to a letter to the editor re: Sentinel node biopsy for early-stage melanoma. Ann Surg (2007) 1.32

Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg (2006) 1.31

Does metastasectomy improve survival in patients with Stage IV melanoma? A cancer registry analysis of outcomes. J Surg Oncol (2011) 1.29

Prospective multicenter trial of staging adequacy in colon cancer: preliminary results. Arch Surg (2006) 1.28

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J Clin Oncol (2013) 1.27

Enhanced survival associated with vitiligo expression during maintenance biotherapy for metastatic melanoma. J Invest Dermatol (2006) 1.26

Practice patterns and outcomes for anorectal melanoma in the USA, reviewing three decades of treatment: is more extensive surgical resection beneficial in all patients? Ann Surg Oncol (2009) 1.25

Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas. Cancer Res (2003) 1.24

Endogenous immune response to gangliosides in patients with confined prostate cancer. Int J Cancer (2005) 1.23

Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors. Mol Cancer Ther (2008) 1.23

Age-related lymphatic dysfunction in melanoma patients. Ann Surg Oncol (2009) 1.22

The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making. Clin Nucl Med (2003) 1.21

Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. J Clin Oncol (2004) 1.20

Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. Ann Surg Oncol (2007) 1.19

Detection of circulating tumor cells in early-stage breast cancer metastasis to axillary lymph nodes. Clin Cancer Res (2007) 1.19

Improved survival for stage IV melanoma from an unknown primary site. J Clin Oncol (2009) 1.18

Effect of lymphatic mapping on the new tumor-node-metastasis classification for colorectal cancer. J Clin Oncol (2003) 1.18

Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res (2006) 1.18

Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res (2009) 1.17

Manipulation of the primary breast tumor and the incidence of sentinel node metastases from invasive breast cancer. Arch Surg (2004) 1.16

Melanoma recurrence patterns after negative sentinel lymphadenectomy. Arch Surg (2005) 1.15

Glycoimmunomics of human cancer: current concepts and future perspectives. Future Oncol (2007) 1.14

B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann Surg (2010) 1.13

Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol (2005) 1.12

The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer (2006) 1.11

Quantitative analysis of melanoma-induced cytokine-mediated immunosuppression in melanoma sentinel nodes. Clin Cancer Res (2005) 1.11

Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Cancer Metastasis Rev (2006) 1.11

Importance of sentinel lymph node biopsy in patients with thin melanoma. Arch Surg (2008) 1.10

AIM1 and LINE-1 epigenetic aberrations in tumor and serum relate to melanoma progression and disease outcome. J Invest Dermatol (2012) 1.09

Human high molecular weight-melanoma-associated antigen: utility for detection of metastatic melanoma in sentinel lymph nodes. Clin Cancer Res (2008) 1.09

mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem (2009) 1.07

B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol (2013) 1.07

Surgery for distant melanoma metastasis. Cancer J (2012) 1.03

Survivin expression by metastatic melanoma predicts poor disease outcome in patients receiving adjuvant polyvalent vaccine. Int J Cancer (2005) 1.03

Survey of ASCO members on management of sentinel node micrometastases in breast cancer: variation in treatment recommendations according to specialty. Ann Surg Oncol (2009) 1.01

Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial. J Clin Oncol (2012) 1.01

Vaccine therapy for melanoma: current status and future directions. Vaccine (2007) 1.00

Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma. Cancer Res (2004) 1.00

Sentinel node biopsy in melanoma: technical considerations of the procedure as performed at the John Wayne Cancer Institute. J Surg Oncol (2010) 1.00

Epicatechins Purified from Green Tea (Camellia sinensis) Differentially Suppress Growth of Gender-Dependent Human Cancer Cell Lines. Evid Based Complement Alternat Med (2006) 0.99

Molecular characterization of inflammatory genes in sentinel and nonsentinel nodes in melanoma. Clin Cancer Res (2007) 0.99

The role of sentinel lymph node biopsy in the management of melanoma. Adv Surg (2007) 0.98

Monocyte-derived IL-10 expression predicts prognosis of stage IV melanoma patients. J Immunother (2007) 0.98

Phase I pilot clinical trial of human IgM monoclonal antibody to ganglioside GM3 in patients with metastatic melanoma. Cancer Immunol Immunother (2003) 0.98

Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother (2012) 0.98

Solitary dermal melanoma: beginning or end of the metastatic process? Ann Surg Oncol (2009) 0.97

Tumor-microenvironment interactions: the fucose-generating FX enzyme controls adhesive properties of colorectal cancer cells. Cancer Res (2004) 0.96

Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol (2003) 0.95

Natural history of melanoma in 773 patients with tumor-negative sentinel lymph nodes. Ann Surg Oncol (2007) 0.95

Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine. J Clin Oncol (2002) 0.94

Brain metastasis is predetermined in early stages of cutaneous melanoma by CD44v6 expression through epigenetic regulation of the spliceosome. Pigment Cell Melanoma Res (2014) 0.93

Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol (2003) 0.93

Molecular tumor markers in the blood: early prediction of disease outcome in melanoma patients treated with a melanoma vaccine. J Clin Oncol (2003) 0.92

The role of lymphatic mapping and sentinel node biopsy in the management of atypical and anomalous melanocytic lesions. J Cutan Pathol (2010) 0.92